Withdrawal Agreement: Proposed Changes

Debate between James Duddridge and Anna Soubry

Monday 7th October 2019 Commons Chamber

[Anna Soubry (Broxtowe) (IGC)]

I am sure, Mr Speaker, that you may not have heard the use of the word “dishonourable” to describe those of us who think that our great country has made a mistake and are doing nothing more than speaking out with the freedom that I thought was at the heart of our democracy. I would have hoped that the hon. Member for South Dorset (Richard Drax) might have withdrawn his comments. In any event, it is very odd that we are all being asked to support a deal, the details of which we know very little of, unless of course our name is Arlene Foster. We want to know the details of these customs arrangements, and of the structures and infrastructure, because of the position in other countries, notably Norway and Sweden. Sweden is a member of the single market and the customs union, and Norway is in the single market but not the customs union, and they have a hard border. May we therefore have these unicorn details please?

[James Duddridge]

I must say that although I am reaching out across the Floor, I have given up on reaching out to the right hon. Lady. There are many Opposition Members and there is still hope for people who will support a plan, but I suspect that under no circumstances will she support a plan, regardless of what we produce and what it says.

Brain Tumours in Children

Debate between James Duddridge and Anna Soubry

Tuesday 3rd September 2013 Westminster Hall

[Anna Soubry]

I am more than happy to add my grateful thanks for the work of Neil and Angela Dickson, and the work of all those who support them. There are many such examples, and funds are often raised for research and to support families or other bits of work.

As my hon. Friend the Member for South West Bedfordshire (Andrew Selous) said, money that goes into research often has the most powerful results. I pay tribute to Headcase cancer trust in my constituency, as I am very much aware of the great work that continues to be needed on brain cancer, which is a pernicious and horrible disease that affects people of all ages, but it seems somehow to be particularly cruel and wicked when it is inflicted on children.

There are a few things that I want to mention before moving on to some of the substantive points raised by my hon. Friend the Member for Esher and Walton. We recognise that we need to do more to bring cancer survival rates up to the level of the best in the world—survival rates have been languishing in the wrong place for too long—so we have an outcome strategy that sets out our ambition to halve the gap between England’s survival rates and those of the best in Europe through saving an additional 5,000 lives every year by 2014-15. We know that the earlier a cancer is diagnosed, the greater the scope for curative treatment, and our strategy therefore prioritises addressing late diagnosis. To support that, we have £450 million over four years going into early diagnosis, which is part of the £750 million of additional funding from the Government for addressing cancer over the spending period. That funding will do much great work that I am happy to identify in a letter to my hon. Friend.

On direct GP access to diagnostic tests, my hon. Friend the Member for Hexham (Guy Opperman) made a good point about having someone within each clinical commissioning group who knows about not only brain cancers and brain tumours but other similar afflictions. As he rightly identifies, when a child has a headache, or when an adult has some other complaint and they are not sure what it is, there could be a more specialist GP who can say, “Maybe this is the sort of case that we need to scan swiftly,” or, “Maybe it needs some other treatment.” That is a very good point, but we need GPs to recognise symptoms that could be indicative of cancer and, where appropriate, to refer patients to more specialist care.

The National Institute for Health and Clinical Excellence has published referral guidelines for suspected cancers, including a section on children, to help GPs and primary care professionals identify children with suspected cancer. The Department of Health published guidance in April 2012 on the best practice for what we call “referral pathways” for GPs.

When GPs suspect a brain tumour, they are able urgently to refer patients for special care using the two-week urgent referral pathway, and I have been helpfully supplied with some figures that I hope will give comfort and encouragement. Some 95.5% of patients were seen by a specialist within two weeks of an urgent GP referral for suspected cancer—that is for all cancers—in the first quarter of 2013-14, and 96.4% of patients urgently referred by their GP for suspected brain or central nervous system tumours were seen by a specialist within the two-week period. In the first quarter of 2013-14, 96.4% of patients in England urgently referred by their GP for a suspected children’s cancer were seen by a specialist within the two-week period. I think those are good figures, but of course we can always do better.

[James Duddridge]

Will the Minister give way?

[Anna Soubry]

Briefly, yes.

[James Duddridge]

Those are the figures for being seen by a consultant, but are there figures for when surgery actually takes place? Will the Minister provide us with those figures after the debate?

[Anna Soubry]

I do not believe I have those figures in front of me, but I am more than happy to provide them to everyone who has taken part in the debate. My official is indicating that we have the figures, and it is not a problem for me to give them to my hon. Friend.

NHS England now monitors the use of key diagnostic tests through the diagnostic imaging dataset, and the latest available provisional data for the period from April 2012 to March 2013 show that 28,995 tests—which is about a quarter of all tests—that may have been used to diagnose or discount cancer were requested by GPs under direct access arrangements.

I pay huge tribute to HeadSmart, and of course I welcome its “Be brain tumour aware” campaign and the collaboration between the Brain Tumour Charity, the children’s brain tumour research centre at the university of Nottingham—to which I admit I have a bias, being a Nottinghamshire MP—and the Royal College of Paediatrics and Child Health. I have written to HeadSmart offering encouragement and advising that it could apply to the voluntary sector investment programme for funds to raise awareness of HeadSmart cards in schools. I will continue to work with those great and wonderful charities, and I look forward to seeing them inform the development of our nationally led campaigns.

My hon. Friend the Member for Esher and Walton directly challenges me to take action, and I shall tell him what I will do. I might not completely agree with all that he proposes, but I am more than happy to speak to my colleagues at Public Health England—cancer screening is an obvious priority for Public Health England—about how we can best advance HeadSmart cards in schools. As he knows, of course, public health is now devolved to local authority level. And as he also knows, we are a Government who believe in localism, and therefore it is not for Ministers to tell people what to do, however much we might want to at times.

The idea advanced by my hon. Friend the Member for Brentford and Isleworth is very good. A great deal of work can be done by local MPs. Of course, hon. Members might not know about this, but we can talk afterwards about how we can alert our colleagues throughout the House to what can be done. A letter from a local Member of Parliament to their director of public health, or to the chair of their health and wellbeing board, will frankly have more weight than any letter from me.